> They reviewed 17 clinical studies that evaluated seven different monoclonal antibodies. All of these were placebo-controlled, and all were funded by the developers of the different drugs. This covers over 20,000 participants, and the results are clear and consistent across the entire data set, from what I can see: these drugs do not work.

>The evidence from all these clinical trials did convince the Cochrane reviewers of one thing, though: taking these drugs increases the risk of amyloid-related imaging abnormalities. It is extremely concerning when the most definitive data about an entire class of drugs is about their unwanted side effects. I do not see why these antibodies should be on the market.